• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种新型自膨式球囊治疗难治性良性食管狭窄:前瞻性、单臂、多中心研究。

A novel self-inflatable balloon for treating refractory benign esophageal strictures: a prospective, single-arm, multicenter study.

机构信息

Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing.

The Second Hospital of Hebei Medical University, Shijiazhuang.

出版信息

Int J Surg. 2024 Apr 1;110(4):2055-2064. doi: 10.1097/JS9.0000000000001120.

DOI:10.1097/JS9.0000000000001120
PMID:38668658
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11020001/
Abstract

BACKGROUND AND AIM

Current treatments for refractory benign esophageal strictures (BESs) often take several years and have poor effects. The authors propose a novel method of self-help inflatable balloon (SHIB) and evaluate its efficacy and safety.

METHODS

A prospective, multicenter study was conducted from January 2019 to March 2022. All enrolled patients were diagnosed with refractory BESs and received SHIB. The primary endpoint was the clinical success rate at 12 months after removing SHIB. The secondary endpoints were the number of days of placing SHIB, and changes from baseline in BMI and health-related quality of life at 1, 3, 6, and 12 months.

RESULTS

The clinical success rate was 51.2% (21/41) with the median days of placing SHIB being 104.0 days (range: 62.0-134.5 days), which was higher in the endoscopic group compared to the caustic and surgery groups (63.3 vs. 28.6% vs. 0, P=0.025). All patients (100%) showed significant improvement in dysphagia scores during placing SHIB. Although 20 patients (48.8%) experienced recurrent stricture, the median stricture length was decreased (P<0.001) and the median intervention-free interval was prolonged (P<0.001). In all patients, the mean BMI at and health-related quality of life at 1, 3, 6, and 12 months were significantly increased compared with baseline (P<0.05). On multivariate analysis, stricture etiology and wearing time were independent predictors of recurrent stricture.

CONCLUSIONS

The SHIB has high efficacy and safety in treating refractory BESs of different origins, especially for endoscopic resection. Stricture etiology and wearing time were independent predictors of recurrent stricture.

摘要

背景与目的

目前治疗难治性良性食管狭窄(BES)的方法往往需要数年时间,且效果不佳。作者提出了一种新型的自膨式气囊(SHIB)治疗方法,并评估其疗效和安全性。

方法

这是一项前瞻性、多中心研究,于 2019 年 1 月至 2022 年 3 月进行。所有入组患者均诊断为难治性 BES,并接受 SHIB 治疗。主要终点为 SHIB 取出后 12 个月的临床成功率。次要终点为 SHIB 放置天数,以及 1、3、6 和 12 个月时 BMI 和健康相关生活质量的变化。

结果

临床成功率为 51.2%(21/41),SHIB 放置中位数为 104.0 天(范围:62.0-134.5 天),内镜组高于腐蚀性和手术组(63.3% vs. 28.6% vs. 0,P=0.025)。所有患者(100%)在放置 SHIB 期间吞咽困难评分均显著改善。尽管 20 名患者(48.8%)出现再狭窄,但狭窄长度中位数降低(P<0.001),无干预间隔时间延长(P<0.001)。所有患者在 1、3、6 和 12 个月时的平均 BMI 和健康相关生活质量均显著高于基线(P<0.05)。多变量分析显示,狭窄病因和佩戴时间是再狭窄的独立预测因素。

结论

SHIB 治疗不同病因难治性 BES 的疗效和安全性较高,尤其适用于内镜下切除。狭窄病因和佩戴时间是再狭窄的独立预测因素。

相似文献

1
A novel self-inflatable balloon for treating refractory benign esophageal strictures: a prospective, single-arm, multicenter study.一种新型自膨式球囊治疗难治性良性食管狭窄:前瞻性、单臂、多中心研究。
Int J Surg. 2024 Apr 1;110(4):2055-2064. doi: 10.1097/JS9.0000000000001120.
2
Self-help inflatable balloon versus autologous skin-grafting surgery for preventing esophageal stricture after complete circular endoscopic submucosal dissection: a propensity score matching analysis.自膨式球囊与自体皮肤移植术预防完全环周内镜黏膜下剥离术后食管狭窄的效果比较:倾向评分匹配分析。
Surg Endosc. 2023 May;37(5):3710-3719. doi: 10.1007/s00464-022-09789-4. Epub 2023 Jan 17.
3
Endoscopic and surgical treatment of refractory caustic esophageal strictures.难治性腐蚀性食管狭窄的内镜及手术治疗
Surg Endosc. 2025 May 30. doi: 10.1007/s00464-025-11820-3.
4
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
8
Efficacy and safety of allogeneic mesenchymal precursor cells with and without hyaluronic acid for treatment of chronic low back pain: A prospective, randomized, double blind, concurrent-controlled 36-month study.含透明质酸与不含透明质酸的同种异体间充质前体细胞治疗慢性下腰痛的疗效和安全性:一项前瞻性、随机、双盲、同期对照的36个月研究。
Spine J. 2025 Mar 31. doi: 10.1016/j.spinee.2025.03.015.
9
Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluation.侵入性尿动力学检查在难治性膀胱过度活动症女性患者管理中的应用:FUTURE,一项优效性随机对照试验及经济学评估
Health Technol Assess. 2025 Jul;29(27):1-139. doi: 10.3310/UKYW4923.
10
Intermittent self-dilatation for urethral stricture disease in males.男性尿道狭窄疾病的间歇性自我扩张
Cochrane Database Syst Rev. 2014 Dec 19;2014(12):CD010258. doi: 10.1002/14651858.CD010258.pub2.

本文引用的文献

1
Peroral submucosal endoscopic stricturotomy - a novel third-space approach for a complex anastomotic stricture.经口黏膜下内镜下狭窄切开术——一种治疗复杂性吻合口狭窄的新型第三间隙入路。
Endoscopy. 2023 Dec;55(S 01):E656. doi: 10.1055/a-2063-3465. Epub 2023 Apr 21.
2
Self-Dilation of Refractory Benign Esophageal Strictures.难治性良性食管狭窄的自我扩张
Am J Gastroenterol. 2022 Mar 1;117(3):364-366. doi: 10.14309/ajg.0000000000001589.
3
STROCSS 2021: Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery.
STROCSS 2021:加强外科学队列研究、横断面研究和病例对照研究报告规范。
Int J Surg. 2021 Dec;96:106165. doi: 10.1016/j.ijsu.2021.106165. Epub 2021 Nov 11.
4
Endoscopic Management of Refractory Benign Esophageal Strictures.内镜治疗难治性良性食管狭窄。
Dysphagia. 2021 Jun;36(3):504-516. doi: 10.1007/s00455-021-10270-y. Epub 2021 Mar 12.
5
Assessment of long-term results of repeated dilations and impact of a scheduled program of dilations for refractory esophageal strictures: a retrospective case-control study.评估难治性食管狭窄重复扩张的长期效果及计划性扩张方案的影响:一项回顾性病例对照研究。
Surg Endosc. 2022 Feb;36(2):1098-1105. doi: 10.1007/s00464-021-08376-3. Epub 2021 Mar 1.
6
Comparison of the Efficacy and Safety of Endoscopic Incisional Therapy and Balloon Dilatation for Esophageal Anastomotic Stricture.内镜下切开治疗与球囊扩张治疗食管吻合口狭窄的疗效与安全性比较。
J Gastrointest Surg. 2021 Jul;25(7):1690-1695. doi: 10.1007/s11605-020-04811-3. Epub 2020 Oct 13.
7
Management of Peptic Strictures.消化性狭窄的管理
Am J Gastroenterol. 2020 Jul;115(7):967-970. doi: 10.14309/ajg.0000000000000655.
8
Risk factors and clinical outcomes of endoscopic dilation in benign esophageal strictures: a long-term follow-up study.良性食管狭窄内镜扩张的危险因素和临床结局:一项长期随访研究。
Gastrointest Endosc. 2020 May;91(5):1058-1066. doi: 10.1016/j.gie.2019.12.040. Epub 2020 Jan 7.
9
Outcomes of Endoscopic Dilation in Patients with Esophageal Anastomotic Strictures: Comparison Between Different Etiologies.内镜下扩张治疗食管吻合口狭窄患者的结局:不同病因的比较。
Dysphagia. 2020 Feb;35(1):73-83. doi: 10.1007/s00455-019-10004-1. Epub 2019 Mar 30.
10
Clinical experience of using a novel self-help inflatable balloon to prevent esophageal stricture after circumferential endoscopic submucosal dissection.使用新型自膨式气囊预防环周内镜黏膜下剥离术后食管狭窄的临床经验。
Dig Endosc. 2019 Jul;31(4):453-459. doi: 10.1111/den.13385. Epub 2019 Mar 22.